Back to Search
Start Over
STRN-ALK Fusion in a Case of Malignant Peritoneal Mesothelioma: Mixed Response to Crizotinib, Mode of Resistance, and Brigatinib Sequential Therapy.
- Source :
-
JCO precision oncology [JCO Precis Oncol] 2021 Sep 16; Vol. 5. Date of Electronic Publication: 2021 Sep 16 (Print Publication: 2021). - Publication Year :
- 2021
-
Abstract
- Competing Interests: Stephan Seitz Honoraria: Novartis/Pfizer, GlaxoSmithKline, Lilly, GE Healthcare, AstraZeneca Consulting or Advisory Role: Roche, Pfizer, Lilly, GlaxoSmithKline, AstraZeneca, Novartis, Clovis Oncology No other potential conflicts of interest were reported. Stephan Seitz Honoraria: Novartis/Pfizer, GlaxoSmithKline, Lilly, GE Healthcare, AstraZeneca Consulting or Advisory Role: Roche, Pfizer, Lilly, GlaxoSmithKline, AstraZeneca, Novartis, Clovis Oncology No other potential conflicts of interest were reported.
- Subjects :
- Abdominal Pain etiology
Anaplastic Lymphoma Kinase genetics
Antineoplastic Agents therapeutic use
Calmodulin-Binding Proteins genetics
Female
Humans
Membrane Proteins genetics
Nerve Tissue Proteins genetics
Peritoneum drug effects
Peritoneum physiopathology
Young Adult
Anaplastic Lymphoma Kinase analysis
Calmodulin-Binding Proteins analysis
Crizotinib therapeutic use
Membrane Proteins analysis
Mesothelioma, Malignant drug therapy
Nerve Tissue Proteins analysis
Organophosphorus Compounds therapeutic use
Peritoneum abnormalities
Pyrimidines therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 2473-4284
- Volume :
- 5
- Database :
- MEDLINE
- Journal :
- JCO precision oncology
- Publication Type :
- Academic Journal
- Accession number :
- 34568722
- Full Text :
- https://doi.org/10.1200/PO.21.00184